What is the SURMOUNT Trial? Tirzepatide Research Explained

Understanding the SURMOUNT Trials

If you've been researching tirzepatide for weight loss, you've likely come across references to the SURMOUNT trials. These clinical studies represent some of the most comprehensive research ever conducted on a weight loss medication, and their results have reshaped how we think about treating obesity.

The SURMOUNT trial program (Studies of tirzepatide on the Use and Reduction in weight in non-diabetic patients with Obesity or MOUNT) was designed specifically to evaluate tirzepatide's effectiveness and safety for weight management in people without diabetes. While tirzepatide was initially approved for type 2 diabetes under the brand name Mounjaro, these trials examined whether it could help people lose significant weight even if they didn't have diabetes.

Let's break down what these trials discovered and what the results mean for anyone considering tirzepatide for weight loss.

The SURMOUNT-1 Trial: Landmark Weight Loss Results

SURMOUNT-1 was the largest and most widely cited study in the program. Published in 2022, this trial followed over 2,500 adults with obesity or overweight (with at least one weight-related condition) for 72 weeks.

Participants were randomly assigned to receive either tirzepatide at different doses (5 mg, 10 mg, or 15 mg) or a placebo, all while following a reduced-calorie diet and increased physical activity.

The results were remarkable. People taking the highest dose of tirzepatide lost an average of 20.9% of their body weight—roughly 48 pounds. Even at the lowest dose, participants lost an average of 15% of their starting weight. By comparison, the placebo group lost about 3.1% of their body weight.

What made these results particularly impressive was that more than half of participants on the 15 mg dose achieved at least 20% weight loss, and nearly 9 in 10 lost at least 5% of their body weight—the threshold where meaningful health improvements typically begin.

How the SURMOUNT Trials Were Conducted

The SURMOUNT program consisted of multiple trials examining different aspects of tirzepatide for weight management. These were randomized, double-blind, placebo-controlled studies—the gold standard in medical research.

Participants in SURMOUNT-1 didn't have type 2 diabetes but did have a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition like high blood pressure or sleep apnea.

Everyone in the study received counseling on diet and exercise. They were encouraged to reduce their calorie intake by about 500 calories per day and get at least 150 minutes of physical activity weekly. This design reflects real-world usage—tirzepatide works best when combined with lifestyle modifications.

The medication was administered once weekly via subcutaneous injection, starting at a lower dose and gradually increasing to minimize side effects.

Safety and Side Effects Observed in the Trials

No medication is without potential side effects, and the SURMOUNT trials carefully tracked what participants experienced while taking tirzepatide.

The most common side effects were gastrointestinal issues, including nausea, diarrhea, constipation, and vomiting. These were typically mild to moderate and tended to decrease over time as people's bodies adjusted to the medication. Most occurred during the dose-escalation period.

Serious side effects were relatively rare. About 6-7% of people on tirzepatide discontinued the medication due to adverse events, compared to about 2% in the placebo group. The majority who completed the trial tolerated the medication well.

The trials also monitored cardiovascular markers and found improvements in blood pressure, cholesterol levels, and other metabolic health indicators—benefits that extend beyond weight loss alone.

Beyond SURMOUNT-1: The Broader Research Program

While SURMOUNT-1 gets the most attention, the SURMOUNT program included other important studies. SURMOUNT-2 specifically examined tirzepatide in people with obesity and type 2 diabetes, showing similar impressive weight loss results alongside improved blood sugar control.

SURMOUNT-3 looked at whether tirzepatide could help maintain weight loss after an initial intensive lifestyle intervention, while SURMOUNT-4 examined weight maintenance in people who had already lost weight on tirzepatide.

Together, these studies paint a comprehensive picture of how tirzepatide works across different populations and scenarios. For more information about GLP-1 medications and weight loss, you can explore additional resources at ozarihealth.com/blog.

What the SURMOUNT Trials Mean for You

The SURMOUNT trials provided robust evidence that tirzepatide is one of the most effective weight loss medications currently available. The average weight loss seen in these studies significantly exceeds what's typically achieved with older weight loss medications.

However, it's important to understand that clinical trial results represent averages. Individual experiences vary based on factors like starting weight, adherence to lifestyle changes, genetics, and other health conditions.

The trials also demonstrated that tirzepatide works through multiple mechanisms. As a dual GIP/GLP-1 receptor agonist, it affects both appetite regulation and how your body processes nutrients, which may explain why the weight loss results exceeded those of medications that only target GLP-1 receptors.

These aren't quick fixes, though. The SURMOUNT trials lasted 72 weeks or longer, emphasizing that sustainable weight loss requires time and commitment to both medication and lifestyle changes.

Key Takeaways

• The SURMOUNT trials demonstrated that tirzepatide is highly effective for weight loss, with participants losing an average of 15-21% of their body weight depending on the dose, significantly more than placebo.
• Tirzepatide was generally well-tolerated, with mostly mild to moderate gastrointestinal side effects that typically improved over time.
• These results came from combining medication with lifestyle changes, including reduced calorie intake and regular physical activity, showing that tirzepatide works best as part of a comprehensive approach.
• The trials included thousands of participants over extended periods, providing robust evidence for both effectiveness and safety in people with and without diabetes.

Frequently Asked Questions

How long did participants take tirzepatide in the SURMOUNT trials?

The main SURMOUNT-1 trial lasted 72 weeks (about 17 months), with participants receiving weekly injections throughout this period. Some participants in extension studies continued even longer. The trials were designed to assess long-term weight loss and maintenance rather than short-term results.

Did everyone in the SURMOUNT trials lose weight on tirzepatide?

While the majority of participants experienced significant weight loss, individual results varied. At the highest dose, about 89% of people lost at least 5% of their body weight, and about 57% lost 20% or more. A small percentage didn't respond as well, which reflects the reality that no medication works identically for everyone.

Were the SURMOUNT trial participants required to diet and exercise?

Yes, all participants—including those receiving placebo—were counseled to reduce their calorie intake by approximately 500 calories per day and increase physical activity to at least 150 minutes per week. This design reflects how tirzepatide is intended to be used in real-world settings: as part of a comprehensive weight management program that includes lifestyle modifications.

At Ozari Health, we offer compounded Semaglutide and Tirzepatide as low as $99/month, prescribed by licensed providers and shipped to your door. Learn more at ozarihealth.com.

Reviewed by the Ozari Clinical Content Team (OCCT) — health writers and wellness professionals specializing in GLP-1 therapy and metabolic health. This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.